We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Blueprint Medicines’ Avyakit Approved for Treating Rare Organ Disease
Blueprint Medicines’ Avyakit Approved for Treating Rare Organ Disease
The FDA approved Blueprint Medicines’ Ayvakit (avapritinib) for treating adults with advanced systemic mastocytosis (SM), a group of rare diseases in which white blood cells accumulate in various organs.